Quick Answer
GoodRx Holdings, Inc. reported R&D Expense of $121.03 million for fiscal year 2025.
GoodRx Holdings, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $121.03M | -2.2% |
| 2024 | $123.75M | -8.9% |
| 2023 | $135.84M | -5.1% |
| 2022 | $143.14M | +13.7% |
| 2021 | $125.86M | +103.6% |
| 2020 | $61.82M | +111.0% |
| 2019 | $29.30M | -33.2% |
| 2018 | $43.89M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $31.01M | +2.9% | +3.6% |
| June 30, 2025 | $29.93M | -3.0% | -3.9% |
| March 31, 2025 | $31.14M | +0.4% | +3.3% |
| September 30, 2024 | $30.14M | -23.9% | -2.3% |
| June 30, 2024 | $30.85M | -1.4% | -0.5% |
| March 31, 2024 | $31.02M | -5.7% | -21.7% |
| September 30, 2023 | $39.61M | +10.3% | +26.6% |
| June 30, 2023 | $31.29M | -11.6% | -4.9% |
- GoodRx Holdings, Inc. showed a decrease of -2.2% in R&D Expense compared to the prior fiscal year.
- Over the 2018–2025 period, GoodRx Holdings, Inc.’s r&d expense has grown by 175.7% (from $43.89 million to $121.03 million).
- The most recent figure is from GoodRx Holdings, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: